An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)

Trial Profile

An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions
  • Sponsors Versartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jan 2017 According to Versartis Media release, data will be presented at the Endocrine Society 2017 annual meeting.
    • 26 Sep 2016 According to Versartis Media release data from the Phase 2 stage will be submitted to a scientific conference during the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top